Atara Biotherapeutics (ATRA) Depreciation & Amortization (CF) (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Depreciation & Amortization (CF) came in at $29000.0 in Q1 2026, down 98.38% YoY from $1.8 million in Q1 2025, and down 40.82% on a QoQ basis from $49000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $29000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 98.38% year-over-year to $29000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $350000.0 (down 93.58% YoY) and the FY2025 annual result came in at $2.1 million, down 58.11% from the prior year.
- Depreciation & Amortization (CF) eased to $29000.0 in Q1 2026, from $49000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.8 million in Q1 2025 to a low of $29000.0 in Q1 2026.
- A 5-year average of $1.0 million and a median of $1.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) advanced 29.04% — and 2026, when it tumbled 98.38%.
- Tracing ATRA's Depreciation & Amortization (CF) over 5 years: stood at $1.3 million in 2022, then declined by 3.98% to $1.2 million in 2023, then dropped by 8.71% to $1.1 million in 2024, then sank by 95.55% to $49000.0 in 2025, then sank by 40.82% to $29000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $29000.0 (Q1 2026), $49000.0 (Q4 2025), and $36000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14,000.00 |
| Jun 30, 2026 | 14,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 236,000.00 |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.39 Mn |